Eton Pharmaceuticals
ETON | NASDAQ
$63.88
-$0.05 (-0.08%)
At close: Nov 16, 2026, 4:00 PM ET
$63.77
-$0.11 (-0.17%)
After-hours:
Nov 16, 2026, 7:52 PM ET
Eton Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Key Executives
| Name | Position |
|---|---|
| Sean E. Brynjelsen | President, Chief Executive Officer & Director |
| Danka Radosavljevic | Chief Operating Officer |
| Judith Matthews | Chief Financial Officer & Secretary |
| David Krempa | Chief Business Officer |
| Ipek Erdogan-Trinkaus | Chief Commercial Officer |
| James R. Gruber | Consultant |
| Scott Grossenbach | Senior Vice President of Sales Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 14, 2026 | 8-K | Current Report |
| Oct 06, 2026 | 4 | Filing |
| Sep 28, 2026 | 8-K | Current Report |
| Aug 31, 2026 | 4/A | [Amend] Filing |
| Aug 28, 2026 | 4 | Filing |
| Aug 24, 2026 | 4 | Filing |
| Aug 20, 2026 | 4 | Filing |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 13, 2026 | 8-K | Current Report |
| Aug 12, 2026 | 3 | Filing |
Eton Pharmaceuticals
| Country | United States |
| IPO Date | Nov 14, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Sean E. Brynjelsen |
Contact Details
21925 W. Field Parkway Deer Park,
Illinois 60010-7278 United States
Stock Details
| Ticker Symbol | ETON |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001710340 |
| CUSIP Number | 29772L108 |
| ISIN Number | US29772L1089 |
| SIC Code | 2834 |
Recent News
- 18 hours ago / seekingalpha.comEton Pharmaceuticals: The Commercial Model Is Finally Scaling
- 11 days ago / zacks.comEton Q3 Earnings Call Highlights Growth and Pipeline Expansion
- 11 days ago / marketbeat.comEton Pharmaceuticals Q3 Earnings Call Highlights
- 11 days ago / seekingalpha.comEton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call Transcript
- 11 days ago / zacks.comEton Pharmaceuticals, Inc. (ETON) Q3 Earnings and Revenues Surpass Estimates
- 15 days ago / zacks.comETON Gears Up to Report Q3 Earnings: What Can Investors Expect?
- 19 days ago / globenewswire.comEton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
- 1 month ago / globenewswire.comEton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
- 1 month ago / zacks.comETON Stock Surges 108% in Six Months: Here's What You Need to Know
- 2 months ago / globenewswire.comEton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
Add to Watchlist
Select watchlists to add or remove ETON